Antitumor antisense oligonucleotides
US6018042A · kind A · utility
25Cited by
1References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 20, 1997 |
| Grant date | Jan 25, 2000 |
| Priority date | — |
| Expiry date | Aug 20, 2017 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/158
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to deoxyribo- and ribo-oligonucleotides and derivatives thereof, as well as pharmaceutical preparations, therapies, diagnostics and commercial research reagents in relation to disease states which respond to modulation of the synthesis of the enzyme S-adenosylmethionine decarboxylase (SAMDC). In particular, the invention relates to antisense oligonucleotides and oligonucleotide derivatives specifically hybridizable with nucleic acids relating to (preferably human) SAMDC. These oligonucleotides and their derivatives have been found to modulate the synthesis of SAMDC in cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.